ANGPTL4 ASO-treated mice were protected from HFD-induced obesity and had improved glucose tolerance and insulin sensitivity and lower circulating levels of serum amyloid A. However, in contrast to Singh, we found significantly lower food intake in mice treated with ANGPTL4 ASO compared with Neg-Ctrl ASO, both at higher and lower doses (33). Here, ANGPTL4 is linked to obesity due to melanocortin 4 receptor deficiency.